<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204648">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000324</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-10754-1</org_study_id>
    <secondary_id>R01-10754-1</secondary_id>
    <nct_id>NCT00000324</nct_id>
  </id_info>
  <brief_title>Tryptophan and Behavior Therapy for Cocaine Abuse - 1</brief_title>
  <official_title>Tryptophan and Behavior Therapy for Cocaine Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of tryptophan vs. placebo, and voucher
      payments vs. a control condition, in the treatment of cocaine dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial uses a 2 by 2 design to compare tryptophan to placebo, and voucher
      incentives vs. a control condition, in the outpatient treatment of cocaine dependence- using
      a relapse prevention model of treatment intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <completion_date>April 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Side effects</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cocaine use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cocaine craving</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Other drug use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychosocial functioning</measure>
  </primary_outcome>
  <enrollment>200</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tryptophan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cocaine dependent

        Exclusion Criteria:

          -  Physically dependent on drugs of abuse other than cocaine

          -  Significant medical or psychiatric illness (besides substance abuse disorder)

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric C Strain, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jones H.E., Johnson, R.E., Bigelow G.E., Strain E.C. Differences at treatment entry between opioid-dependent and cocaine-dependent males and females. Addictive Disorders and Their Treatment 3:110-121, 2004.</citation>
  </reference>
  <reference>
    <citation>Jones HE, Johnson RE, Bigelow GE, Silverman K, Mudric T, Strain EC. Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial. Am J Addict. 2004 Oct-Dec;13(5):421-37.</citation>
    <PMID>15764421</PMID>
  </reference>
  <verification_date>August 2005</verification_date>
  <lastchanged_date>June 2, 2015</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
